U
SGNT

UBS’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

UBS’s Portfolio SGNT Stock Details SGNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$16K Hold
513
– – ﹤0.01% 8320
2014
Q2 		$13K Sell
513
-693
-57% -$15.4K ﹤0.01% 8645
2014
Q1 		$28K Buy
+1,206
New +$26.4K ﹤0.01% 7667
2013
Q4 		– Sell
-2,212
Closed -$45K – 11086
2013
Q3 		$45K Buy
+2,212
New +$49.2K ﹤0.01% 7020

Other funds holding SGNT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.29B AUM 53.44% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

UBS's SGNT Position: Q3 2014 in Review

UBS held its SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) position steady in Q3 2014 at 513 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #8320.

UBS first reported a position in SGNT in Q3 2013 and has held it in 4 quarters since. The position peaked at $45K in Q3 2013. 114 funds tracked by Wall St. Rank hold SGNT as of Q3 2014.

  • UBS held 513 shares of SAGENT PHARMACEUTICALS INC COM STK (DE) worth $16K as of Q3 2014.
  • UBS left its SAGENT PHARMACEUTICALS INC COM STK (DE) share count unchanged in Q3 2014.
  • SAGENT PHARMACEUTICALS INC COM STK (DE) made up ﹤0.01% of UBS's portfolio in Q3 2014, its #8320 holding.
  • UBS first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q3 2013 and has held it in 4 quarters since.
  • UBS's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $45K in Q3 2013.
  • 114 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.